Compare Tata Nifty MidSmall Healthcare Index Fund vs SBI Healthcare Opportunities Fund
Tata Nifty MidSmall Healthcare Index Fund
EquitySectoral-Pharma
SBI Healthcare Opportunities Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.14
1.99
NAV
₹14.47
₹563.66
Fund Started
08 Apr 2024
04 Jun 1999
Fund Size
₹220.69 Cr
₹5870.00 Cr
Exit Load
Exit load of 0.25%, if redeemed within 15 days.
Exit load of 0.50% if redeemed within 15 days
1 Year
10.32%
11.56%
3 Year
-
20.58%
5 Year
-
15.68%
Equity
100.14%
95.53%
Cash
-0.14%
4.41%
Top 10 Holdings
Name | Assets |
|---|---|
Laurus Labs Ltd. | 11.84% |
Lupin Ltd. | 7.57% |
Aurobindo Pharma Ltd. | 7.09% |
Fortis Healthcare Ltd. | 6.16% |
Glenmark Pharmaceuticals Ltd. | 5.40% |
Alkem Laboratories Ltd. | 4.78% |
Mankind Pharma Ltd. | 4.36% |
Ipca Laboratories Ltd. | 4.11% |
Biocon Ltd. | 3.96% |
Gland Pharma Ltd. | 3.55% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.14% |
Divi's Laboratories Ltd. | 7.91% |
Acutaas Chemicals Ltd. | 5.03% |
Apollo Hospitals Enterprise Ltd. | 4.45% |
Torrent Pharmaceuticals Ltd. | 4.42% |
Cipla Ltd. | 4.40% |
Laurus Labs Ltd. | 4.05% |
Max Healthcare Institute Ltd. | 3.80% |
Aurobindo Pharma Ltd. | 3.42% |
Aster DM Quality Care Ltd. | 3.21% |
Name
-
-
Start Date
-
-
Description
The scheme seeks to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
08 Apr 2024
04 Jun 1999
